SCHEMBL23924196

SCHEMBL23924196

O=C(O)N1CC(NS(=O)(=O)c2cccc3cnccc23)C(c2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 9/20 0.48
CHRM1 P11229 3/20 0.45
PRKD3 O94806 3/20 0.44
PRKCG P05129 3/20 0.44
PRKCB P05771 3/20 0.44
PRKCA P17252 3/20 0.44
PRKCH P24723 3/20 0.44
PRKCI P41743 3/20 0.44
PRKCE Q02156 3/20 0.44
PRKCQ Q04759 3/20 0.44
PRKCZ Q05513 3/20 0.44
PRKCD Q05655 3/20 0.44
PRKD1 Q15139 3/20 0.44
MEN1 O00255 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
NFKB1 P19838 2/20 0.44
KMT2A Q03164 2/20 0.44
PRKACA P17612 2/20 0.44
PRKACG P22612 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924195 1.00 P2RX7 (0.48) P2RX7CHRM1PRKD3PRKCGPRKCB
SCHEMBL23951468 0.88 P2RX7 (0.49) P2RX7CHRM1PRKD3PRKCGPRKCB
SCHEMBL23923979 0.80 PRKD3 (0.46) P2RX7PRKD3PRKCGPRKCBPRKCA
SCHEMBL30114565 0.80 PRKD3 (0.46) P2RX7PRKD3PRKCGPRKCBPRKCA
SCHEMBL23951469 0.80 PRKD3 (0.46) P2RX7PRKD3PRKCGPRKCBPRKCA
SCHEMBL23924376 0.77 KMT2A (0.53) MEN1KMT2ALMNASMN1; SMN2MAPK1
SCHEMBL23924378 0.77 KMT2A (0.53) MEN1KMT2ALMNASMN1; SMN2MAPK1
SCHEMBL23924073 0.76 GRIN1 (0.44) P2RX7CHRM1LMNASMN1; SMN2NSD2
SCHEMBL23924075 0.76 GRIN1 (0.44) P2RX7CHRM1LMNASMN1; SMN2NSD2
SCHEMBL23924097 0.76 GRIN1 (0.44) P2RX7CHRM1LMNASMN1; SMN2NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 P2RX7 3078/4885CHRM1 3119/4885PRKD3 1591/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 P2RX7 3078/4885CHRM1 3119/4885PRKD3 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.